Abeona Therapeutics (ABEO) PT Set at $30.00 by HC Wainwright

Abeona Therapeutics (NASDAQ:ABEO) received a $30.00 price objective from HC Wainwright in a note issued to investors on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 91.69% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on ABEO. Royal Bank of Canada started coverage on shares of Abeona Therapeutics in a research report on Thursday, September 14th. They issued an “outperform” rating and a $23.00 target price on the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $21.00 target price on shares of Abeona Therapeutics in a research report on Friday, October 6th. Citigroup started coverage on shares of Abeona Therapeutics in a research report on Tuesday, October 10th. They issued a “buy” rating and a $32.00 target price on the stock. SunTrust Banks started coverage on shares of Abeona Therapeutics in a research report on Wednesday, November 8th. They issued a “buy” rating and a $26.00 target price on the stock. Finally, Maxim Group set a $35.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 20th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $26.10.

Shares of Abeona Therapeutics (ABEO) opened at $15.65 on Thursday. Abeona Therapeutics has a 12 month low of $4.50 and a 12 month high of $22.75. The stock has a market cap of $732.03, a PE ratio of -24.08 and a beta of 2.34.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. The company had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.22 million. research analysts predict that Abeona Therapeutics will post -0.6 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp boosted its position in shares of Abeona Therapeutics by 138.5% in the second quarter. Bank of New York Mellon Corp now owns 99,996 shares of the biopharmaceutical company’s stock worth $640,000 after acquiring an additional 58,067 shares during the last quarter. Schwab Charles Investment Management Inc. acquired a new position in Abeona Therapeutics during the second quarter valued at approximately $264,000. Northern Trust Corp lifted its position in Abeona Therapeutics by 406.3% during the second quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock valued at $1,649,000 after buying an additional 206,775 shares in the last quarter. TIAA CREF Investment Management LLC acquired a new position in Abeona Therapeutics during the second quarter valued at approximately $430,000. Finally, Teachers Advisors LLC acquired a new position in Abeona Therapeutics during the second quarter valued at approximately $284,000. 41.95% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Abeona Therapeutics (ABEO) PT Set at $30.00 by HC Wainwright” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2018/01/06/abeona-therapeutics-abeo-pt-set-at-30-00-by-hc-wainwright.html.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply